SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2,453.39 |
| Enterprise Value ($M) | 2,354.26 |
| Book Value ($M) | 423.44 |
| Book Value / Share | 4.15 |
| Price / Book | 5.79 |
| NCAV ($M) | 346.80 |
| NCAV / Share | 3.40 |
| Price / NCAV | 7.07 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.84 |
| Return on Assets (ROA) | -2.02 |
| Return on Equity (ROE) | -2.81 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.49 |
| Current Ratio | 3.49 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 538.47 |
| Assets | 615.11 |
| Liabilities | 191.67 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -885.11 |
| Net Income | -846.42 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -582.45 |
| Cash from Investing | -244.97 |
| Cash from Financing | 677.77 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Janus Henderson Group Plc | 6.90 | 12.14 | |
| 13G/A | Vanguard Group Inc | 8.23 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 361,242 | 1,903,961 | 18.97 | |
| 791,001 | 3,331,158 | 23.75 | |
| 212,145 | 925,275 | 22.93 | |
| 109,407 | 489,082 | 22.37 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ANRO – Alto Neuroscience, Inc. | ANVS – Annovis Bio, Inc. |
| BHC – Bausch Health Companies Inc. | BMY – Bristol-Myers Squibb Company |
| EBS – Emergent BioSolutions Inc. |
Financial data and stock pages provided by
Fintel.io